042623 Schizophrenia and Bipolar I Disorder CME Info
Schizophrenia and Bipolar I Disorder:
Understanding Patient Needs to Guide Targeted Treatment Approaches
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Schizophrenia & Psychosis Action Alliance (S&PAA).
ACKNOWLEDGEMENT
This activity is supported by educational grants from Alkermes, Inc. and Indivior Inc.
TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
ENDURING CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Enduring Material
The enduring material will be available from April 26, 2023, to April 26, 2024.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
TARGET AUDIENCE
The target audience for the activity are psychologists, psychiatrists, primary care physicians, nurse practitioners, physician assistants in psychiatry and primary care, and other mental health specialists.
ESTIMATED TIME TO COMPLETE
1 hour
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.PsychiatryCareLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
| Name of Faculty or Presenter | Reported Financial Relationship |
|
René S. Kahn, MD, PhD Esther and Joseph Klingenstein Professor & Chair Department of Psychiatry and Behavioral Health System Icahn School of Medicine at Mount Sinai |
Consultant/Advisory Board: Alkermes, Merck, Sunuvion |
|
Christoph U. Correll, MD Professor of Psychiatry Zucker School of Medicine at Hofstra/Northwell Professor and Chair Department of Child and Adolescent Psychiatry Charité University Medicine, Berlin, Germany |
Grant/Research Support: Janssen, Takeda Honoraria for non-CME: AbbVie, Angelini, Aristo, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Takeda, Viatris. Consultant/Advisory Board: AbbVie, Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Gedeon Richter, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Mindpax, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. Non-Mutual funds Stock Ownership/Stock options: Stock option holder only of Cardio Diagnostics, Mindpax, LB Pharma and Quantic Royalties paid to you: UpToDate |
The PIM planners and managers have nothing to disclose. The PlatformQ Health Education, LLC planners and others have nothing to disclose.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Accreditation Support:
Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive.com at 877-394-1306 or at Support@PsychiatryCareLive.com.